Clearside Biomedical, Inc.
CLSDQ
$0.95
$0.1215.14%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.45% | 17.17% | 11.89% | -5.75% | 14.57% |
| Total Depreciation and Amortization | 98.80% | 199.07% | 253.75% | 237.31% | 142.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.77% | -28.11% | -39.11% | -18.12% | -4.81% |
| Change in Net Operating Assets | -9,510.00% | -572.26% | -284.73% | -332.92% | 95.22% |
| Cash from Operations | -12.37% | -13.68% | -20.82% | -36.19% | 21.82% |
| Capital Expenditure | 30.63% | 51.58% | 45.96% | 45.02% | 62.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 203.60% | 203.08% | -- | -- | -- |
| Cash from Investing | 192.38% | 189.95% | 65.68% | 64.10% | -475.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -76.74% | -77.17% | -83.90% | 831.75% | 846.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 239.50% | -50.00% | 25.93% | -- | -185.71% |
| Cash from Financing | -65.19% | -86.00% | -89.32% | 3,870.05% | 1,031.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.48% | 47.15% | -258.29% | 54.35% | 39.71% |